Literature DB >> 20359289

Nanoparticles for tumor targeted therapies and their pharmacokinetics.

Jianqiu Wang1, Meihua Sui, Weimin Fan.   

Abstract

Various types of nanoparticles, such as liposomes, polymeric micelles, dendrimers, superparamagnetic iron oxide crystals, and colloidal gold, have been employed in targeted therapies for cancer. Both passive and active targeting strategies can be utilized for nano-drug delivery. Passive targeting is based on the enhanced permeability and retention (EPR) effect of the vasculature surrounding tumors. Active targeting relies on ligand-directed binding of nanoparticles to receptors expressed by tumor cells. Release of loaded drugs from nanoparticles may be controlled in response to changes in environmental condition such as temperature and pH. Biodistribution profiles and anticancer efficacy of nano-drugs in vivo would be different depending upon their size, surface charge, PEGylation and other biophysical properties. This review focuses on the recent development of nanoparticles for tumor targeted therapies, including physicochemical properties, tumor targeting, control of drug release, pharmacokinetics, anticancer efficacy and safety. Future perspectives are discussed as well.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20359289     DOI: 10.2174/138920010791110827

Source DB:  PubMed          Journal:  Curr Drug Metab        ISSN: 1389-2002            Impact factor:   3.731


  48 in total

1.  Nanoparticle-mediated signaling endosome localization regulates growth cone motility and neurite growth.

Authors:  Michael B Steketee; Stavros N Moysidis; Xiao-Lu Jin; Jessica E Weinstein; Wolfgang Pita-Thomas; Hemalatha B Raju; Siraj Iqbal; Jeffrey L Goldberg
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

Review 2.  [Use of nanoparticles in ophthalomology].

Authors:  I Hahn; P Heiduschka; E Endl; N Eter
Journal:  Ophthalmologe       Date:  2011-09       Impact factor: 1.059

Review 3.  Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics.

Authors:  Elham Hatami; Meena Jaggi; Subhash C Chauhan; Murali M Yallapu
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2020-05-31       Impact factor: 10.680

4.  Thermosensitive liposome formulated indocyanine green for near-infrared triggered photodynamic therapy: in vivo evaluation for triple-negative breast cancer.

Authors:  Colby S Shemesh; Delaram Moshkelani; Hailing Zhang
Journal:  Pharm Res       Date:  2014-11-19       Impact factor: 4.200

Review 5.  Cancer nanotechnology: emerging role of gold nanoconjugates.

Authors:  Rachel A Kudgus; Resham Bhattacharya; Priyabrata Mukherjee
Journal:  Anticancer Agents Med Chem       Date:  2011-12       Impact factor: 2.505

6.  Novel pyridinecarboxaldehyde thiosemicarbazone conjugated magnetite nanoparticulates (MNPs) promote apoptosis in human lung cancer A549 cells.

Authors:  Alireza Habibi; Seyed Ataollah Sadat Shandiz; Ali Salehzadeh; Zeinab Moradi-Shoeili
Journal:  J Biol Inorg Chem       Date:  2019-10-19       Impact factor: 3.358

7.  Biodistribution and pharmacokinetics of Mad2 siRNA-loaded EGFR-targeted chitosan nanoparticles in cisplatin sensitive and resistant lung cancer models.

Authors:  Ana Vanessa Nascimento; Florence Gattacceca; Amit Singh; Hassan Bousbaa; Domingos Ferreira; Bruno Sarmento; Mansoor M Amiji
Journal:  Nanomedicine (Lond)       Date:  2016-03-16       Impact factor: 5.307

8.  Novel self-assembly endows human serum albumin nanoparticles with an enhanced antitumor efficacy.

Authors:  Dawei Ding; Xiaolei Tang; Xiaoli Cao; Jinhui Wu; Ahu Yuan; Qian Qiao; Jing Pan; Yiqiao Hu
Journal:  AAPS PharmSciTech       Date:  2013-11-28       Impact factor: 3.246

9.  Applications of nanoparticle drug delivery systems for the reversal of multidrug resistance in cancer.

Authors:  Yinghong Huang; Susan P C Cole; Tiange Cai; Y U Cai
Journal:  Oncol Lett       Date:  2016-05-17       Impact factor: 2.967

10.  Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma.

Authors:  Raghavendra Gowda; SubbaRao V Madhunapantula; Arati Sharma; Omer F Kuzu; Gavin P Robertson
Journal:  Mol Cancer Ther       Date:  2014-07-31       Impact factor: 6.261

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.